GSK, just one week after completing the acquisition of Nuvalent, has secured FDA accelerated approval for Jideytro (zidesamtinib), its first novel lung cancer therapy. This approval, which is approximately two months ahead of the initially anticipated review date of September 18, 2026, was expedited through the Breakthrough Therapy and Orphan Drug designations. This achievement allows GSK to establish its initial lung cancer treatment portfolio, diversifying its revenue stream, which has historically been concentrated on HIV therapies and vaccines, and solidifying its presence in the oncology market.

Jideytro, a next-generation ROS1-targeted therapy, has been developed to treat patients with non-small cell lung cancer (NSCLC) who have ROS1 gene mutations, representing approximately 1-2% of this patient population. It has demonstrated compelling clinical data, overcoming the limitations of existing treatments. In the global Phase 1/2 ARROS-1 trial, Jideytro achieved an objective response rate (ORR) of 44% in 117 patients who had previously received targeted therapy. Furthermore, the duration of response (DOR) was 82% at 6 months and 69% at 12 months, indicating long-term efficacy. Notably, Jideytro exhibits potent inhibitory effects in patients with brain metastases and those with major resistance mutations (e.g., ROS1 G2032R) that develop after treatment with existing targeted therapies. Its ability to cross the blood-brain barrier (BBB) makes it a promising treatment option for patients with brain metastases, garnering significant attention within the industry.

This approval represents a significant immediate commercial success for GSK, coming shortly after the completion of the $10.6 billion acquisition of Nuvalent on July 15, 2026. GSK has been actively expanding its oncology pipeline through the acquisitions of Jemperli and Zejula, as well as partnerships with Hansoh Pharma and IDRx. The rapid approval of Jideytro is expected to significantly shorten the return on investment (ROI) period. Market analysts believe that this success will further enhance the prospects for the approval of neladalkib, another key asset from Nuvalent and a ROS1-targeted therapy currently under FDA review, thereby strengthening GSK's long-term growth potential.

The global market for ROS1-targeted therapies is projected to grow rapidly from approximately $4.8 billion in 2025 to $10.7 billion in 2034. However, the market is already highly competitive, with established players such as Pfizer's Xalkori (crizotinib), Roche's Rozlytrek (entrectinib), and Bristol Myers Squibb's Augtyro (repotrectinib). Existing drugs have limitations in terms of resistance development and high side effect profiles, which can limit long-term use. Jideytro, with its superior selectivity and ability to overcome resistance, is expected to rapidly penetrate the second-line treatment market. With approximately 50,000 new ROS1-positive NSCLC patients diagnosed annually worldwide, the long-term usability of Jideytro is expected to establish it as a stable and sustainable revenue generator for GSK.